Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Toripalimab in Renal Cell Carcinoma: NCT07571551 Clinical Landscape Report 2026
16 September 2026
NCT07571551 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RN-1701 in Large B-cell lymphoma: NCT07563543 Clinical Landscape Report 2026
16 September 2026
NCT07563543 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxolitinib in Metastatic Renal Cell Carcinoma: NCT07566897 Clinical Landscape Report 2026
16 September 2026
NCT07566897 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zemprocitinib in Renal Cell Carcinoma: NCT07564232 Clinical Landscape Report 2026
16 September 2026
NCT07564232 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY-4256984 in Amyotrophic Lateral Sclerosis: NCT07571174 Clinical Landscape Report 2026
16 September 2026
NCT07571174 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab biosimilar (Mabscale) in Diffuse large B-cell lymphoma recurrent: NCT07570017 Clinical Landscape Report 2026
16 September 2026
NCT07570017 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Nerandomilast in Idiopathic Pulmonary Fibrosis: NCT07570888 Clinical Landscape Report 2026
16 September 2026
NCT07570888 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma: NCT07569042 Clinical Landscape Report 2026
16 September 2026
NCT07569042 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IM-1617 in Esophageal Carcinoma: NCT07578571 Clinical Landscape Report 2026
16 September 2026
NCT07578571 clinical landscape for Esophageal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bmab1800 (Biocon Biologics UK Ltd.) in Melanoma: NCT07581509 Clinical Landscape Report 2026
16 September 2026
NCT07581509 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IASO 207 in Chronic Lymphocytic Leukemia: NCT07574346 Clinical Landscape Report 2026
16 September 2026
NCT07574346 clinical landscape for Chronic Lymphocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cannabigerol in Bladder Cancer: NCT07577999 Clinical Landscape Report 2026
16 September 2026
NCT07577999 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.